# To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer

> **NCT03676192** · PHASE3 · COMPLETED · sponsor: **Celltrion** · enrollment: 689 (actual)

## Conditions studied

- Adenocarcinoma of Lung

## Interventions

- **DRUG:** CT-P16
- **DRUG:** Avastin

## Key facts

- **NCT ID:** NCT03676192
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-01
- **Primary completion:** 2021-04-22
- **Final completion:** 2023-09-19
- **Target enrollment:** 689 (ACTUAL)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03676192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03676192, "To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03676192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*